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ABSTRACT
Background. We investigated ten-year trends in deceased donor kidney quality expressed as the 
kidney donor risk index (KDRI) and subsequent effects on survival outcomes in a European transplant 
population.
Methods. Time trends in the crude and standardised KDRI between 2005-2015, by recipient age, sex, 
diabetic status, and country were examined in 24,177 adult kidney transplant recipients in seven 
European countries. We determined five-year patient and graft survival probabilities and the risk of 
death and graft loss by transplant cohort (cohort 1: 2005-2006, cohort 2: 2007-2008, cohort 3: 2009-
2010) and KDRI quintile.
Results. The median crude KDRI increased by 1.3% annually from 1.31 (interquartile range, IQR: 1.08-
1.63) in 2005 to 1.47 (IQR: 1.16-1.90) in 2015. This increase i.e., lower kidney quality, was driven 
predominantly by increases in donor age, hypertension and donation after circulatory death. With 
time, the gap between the median standardised KDRI in the youngest (18-44 years) and eldest (>65 
years) recipients widened. There was no difference in the median standardised KDRI by recipient sex. 
The median standardised KDRI was highest in Austria, the Netherlands, and Basque Country (Spain). 
Within each transplant cohort, the 5-year patient and graft survival probability were higher for the 
lowest KDRIs. There was no difference in the patient and graft survival outcomes across transplant 
cohorts, however over time the survival probabilities for the highest KDRIs improved.
Conclusions. The overall quality of deceased donor kidneys transplanted between 2005-2015 has 
decreased and varies between age groups and countries. Overall patient and graft outcomes remain 
unchanged. 
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KEY LEARNING POINTS
What is already known about this subject?
Deceased donor kidneys with higher KDRI scores have worse survival outcomes than those with 
lower KDRI scores. To meet demands, older and more marginal kidneys are being used. It is not 
known if the increased use of marginal kidneys has resulted in worse transplant outcomes over time.
What this study adds? 
Over a ten-year period, transplant recipients over 45 years old have received kidneys with 
increasingly higher KDRIs i.e., worse quality. These kidneys are increasingly coming from donors that 
are older, more likely to have a diagnosis of hypertension and retrieved from donors after circulatory 
death, though this varied between countries. This has not translated to poorer five-year kidney 
transplant outcomes.
What impact this may have on practice or policy? 
As life expectancy in the general population increases, and the prevalence of diabetes mellitus, 
hypertension and obesity increases it is likely that we will continue to see poorer quality donor 
kidneys. To avoid this translating into worse kidney transplant outcomes the transplant community 
should focus on identifying therapies and/or preventative strategies aimed at improving kidney 
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INTRODUCTION
In order to meet the demand of kidneys for transplantation, which continues to exceed the current 
supply (1, 2), an increasing number of marginal kidneys are being utilised (3, 4). Marginal kidneys 
have been associated with worse graft survival outcomes (5). The kidney donor risk index (KDRI), 
derived from ten deceased donor factors, provides an estimate of how long a deceased donor kidney 
allograft can be expected to function for, relative to ‘the median’ deceased donor kidney retrieved in 
the United States (US) in the previous calendar year (6). The KDRI has now been validated in several 
European countries (7-9). Lower KDRI scores represent a higher estimated graft survival time, 
whereas higher KDRI scores represent a lower estimated graft survival time (10). A deceased kidney 
donor in 2017 with a standardised KDRI score of 1.5 equates to a 1.5 times higher relative risk of 
allograft failure compared to the ‘median’ deceased donor kidney from 2016. Given that the KDRI is 
standardised to the median donor of the previous year, the reference group is changing on an annual 
basis, and, as a consequence, a donor represented by a KDRI of 1.5 in one year, may not be same as a 
donor represented by a KDRI of 1.5 in previous years. By standardising the KDRI over a number of 
years to the same reference donor, i.e. the median deceased donor in one chosen year, one has a 
quantitative measure with which to assess the quality of deceased donor kidneys in a given 
population and across populations over time. 
Using data from kidney and transplant registries in seven European countries we investigated the 
trends in the quality of transplanted deceased donor kidneys between 2005 and 2015, expressed as 
KDRI scores, and standardised to a reference KDRI score. We identified annual trends in standardised 
KDRI scores over a ten-year period by recipient sex, recipient age group, recipient diabetic status, 
and country of transplantation. Furthermore, we assessed patient and graft survival outcomes by 










Data from the ERA-EDTA Registry with additional data collection from nine individual kidney and 
transplant registries in seven countries were used; Austrian dialysis and transplant registry, 
Eurotransplant, Danish Nephrology Registry, Scandiatransplant, Information unit about renal patients 
from the Basque Country, Dutch Transplant Foundation, Norwegian Renal Registry, Slovenian Renal 
Registry and United Kingdom Transplant Registry held by NHS Blood & Transplant. The recipients 
included in the study were restricted to those aged ≥18 years at the time of first, kidney only, ABO-
compatible transplants performed during 1st January 2005 to 31st December 2015. No data were 
collected regarding deceased donors from whom kidneys were subsequently not recovered or 
discarded once recovered. All national and regional kidney registries contributing data to the ERA-
EDTA Registry followed their national legislation regarding ethics committee approval. 
Data analysis
Missing data
Overall, 80% of cases had complete donor details except for donor ethnicity and hepatitis C (HCV) 
status (Supplemental Table 1a and 1b). Where the donor ethnicity and HCV status were unavailable, 
we assumed that, in this European setting, the donor was Caucasian and HCV negative. Based on the 
differences between the complete cases and the cases with missing variables, it was concluded that 
with the exception of donor diabetes and hypertension in Norway, the data was missing completely 
at random, therefore the missing variables were imputed in SAS using the multiple imputation 
procedure (proc mi). The donor variables included in the imputation model were donor age, height, 
weight, prior diagnosis of hypertension, prior diagnosis of diabetes mellitus, creatinine, cause of 
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Five imputed datasets were created. Log transformations were used for non-normally distributed 
data, which were then transformed back to their original form before the analysis (11). Missing 
variables were imputed by country for example only donor and recipient data from Austria was used 
to impute Austria’s missing data.
Evaluating time trends in the KDRI
Using the donor characteristics and the KDRI beta coefficients as determined by Rao et al (6) we 
calculated the ‘donor-only’ KDRI for each individual donor (Box 1). We then determined the 
distribution of the crude KDRI for the years 2005, 2010 and 2015, overall and by recipient sex, 
recipient age group (18-44, 45-54, 55-64, ≥65 years), recipient diabetic status and country. These 
data were presented as violin plots which have the advantages of both box plots, thereby allowing 
the visualisation of summary statistics, and density traces, thereby allowing visualisation of the data 
distribution.
We examined for time trends in KDRI between 2005 and 2015. To have a meaningful comparison of 
the KDRI over time, a scaling factor was applied. In these analyses for all the years in question, we 
used the median KDRI from 2005 as the scaling factor, thereby giving the 2005 median KDRI of the 
whole group a score of 1. The same groups as for the distribution of the crude KDRI were examined, 
i.e.
1. All countries/regions combined: overall and by recipient sex, recipient age group, and 
recipient diabetic status.
2. Time trends in the individual countries/regions. 
Time trends in the standardised KDRI were examined using Joinpoint regression (12). The year was 
taken as the explanatory variable and the scaled median KDRI as the outcome. The average annual 
percentage change (AAPC) was computed using Poisson regression as provided by the Joinpoint 
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Survival analysis 
Kaplan-Meier and Cox Regression were used to calculate five-year patient and graft survival 
probabilities and the risk of death and graft loss respectively by transplant cohort and by KDRI. To 
allow for analysis of five-year follow up, the recipients were divided into three transplant cohorts; 
cohort 1: 2005-2006; cohort 2: 2007-2008; and cohort 3: 2009-2010. Thereafter the cohorts were 
further subdivided by KDRI quintiles, which had been standardised to the median 2005 KDRI. The 
KDRI quintiles were 0.45-<0.79; 0.79-<0.96; 0.96-<1.15; 1.15-<1.45; ≥1.45. The date of 
transplantation was taken as the starting point, and the patients were followed until the event of 
interest. For patient survival the event of interest was death. For graft failure, the events of interest 
were either a return to dialysis, re-transplantation, or death with a functioning allograft. Patients 
were censored for loss to follow-up and the end of the study period was set as the 31st December 
2015. In the adjusted analysis, we adjusted for recipient age at transplantation, recipient sex, primary 
kidney diagnosis, cold ischaemia time (CIT), human leukocyte antigen (HLA) mismatch score, and 
country of transplantation.
Sensitivity analysis
A sensitivity analysis of complete cases i.e., only cases where all donor variables except for donor 
HCV status and ethnicity were available was performed. To account for the increasing number of 
DCD transplants over time, the crude and standardised KDRI scores for DBD transplants were 
calculated. 
A two-tailed p-value of <0.05 was considered statistically significant. Analyses were performed using 
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RESULTS
We included 24,177 recipients, transplanted between 2005 and 2015. During this period the median 
recipient age rose from 53 (interquartile range, IQR: 43.0-61.5) to 55 years (IQR: 45.0-65.0) and the 
percentage of recipients with a diagnosis of diabetes mellitus rose from 12.5% to 17.0%. The median 
deceased kidney donor age rose from 50 years (IQR: 38-59) in 2005 to 55 (IQR: 44-65) in 2015 (Table 
1). The percentage of donors with a history of hypertension (23% to 30%), diabetes mellitus (4% to 
8%), and severe obesity (body mass index >35 kg/m2; 4% to 7%) increased.
Trends in crude KDRI
For all countries combined, the median crude KDRI was 1.31 (IQR: 1.08-1.63), 1.41 (IQR: 1.13-1.81), 
and 1.47 (IQR: 1.16-1.90) in 2005, 2010 and 2015, respectively (Figure 1 top left). The median crude 
KDRIs presented for all countries combined can be found in Figure 1 and Supplemental Table 2, and 
by individual country can be found in Supplemental Figure 1 and Supplemental Table 2. 
Trends in standardised KDRI
When standardised to the median KDRI from the total group in 2005 one can objectively visualise 
annual changes in the ‘median donor’ based on ten deceased donor factors. Between 2005 and 2015 
this standardised median donor KDRI increased from 1.00 to 1.13, giving an average annual 
percentage change of 1.3% (95%CI: 0.6-2.0, Figure 2a, Supplementary Table 3). The standardised 
median donor KDRI increased for both female and male recipients by an average annual percentage 
change of 1.5% (95%CI: 1.0-2.0) and by 1.2% (95%CI: 0.8-1.6) respectively, with no differences 
between the sexes (p=0.851, Figure 2b). There appeared to be a trend towards a decline in the 
standardised median KDRI for the recipients aged 18-44 (AAPC -0.3%, 95%CI: -0.6-2.3). Over time the 
gap between the standardised KDRI in the youngest and oldest recipients widened. The standardised 
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(Figure 2c, Supplementary Table 3). Recipients with diabetes mellitus remained in receipt of lower 
quality donor kidneys compared to recipients without diabetes mellitus throughout the 10-year 
period (p<0.001), though the KDRI increased for both diabetic and non-diabetic recipient groups 
(Figure 2d, Supplementary Table 3).
Overall Austria, Basque Country (Spain), and the Netherlands had higher annual standardised median 
KDRIs than Norway and Slovenia (Figure 3, Supplementary Table 3). Austria, Basque Country (Spain), 
and the Netherlands continued to have higher than average standardised KDRIs when recipients 
were stratified by older age (Supplemental Figure 2). The driving factors behind these differences 
varied by country (Table 2). The high standardised KDRI in Austria, Basque Country (Spain), and the 
Netherlands was mainly driven by a higher proportion of deceased donors aged >50 years and 
donors with a diagnosis of diabetes mellitus. In addition, within the Netherlands and the UK almost 
50% of donors were DCD donors, whilst they only made up 5% of donors in Norway and 0% of donors 
in Slovenia and Denmark. 
Survival analysis was performed on 11,767 first transplant recipients transplanted between 2005-
2010. Demographic data is given in Table 3, and Figure 4 presents the unadjusted patient and graft 
survival curves by time cohort and KDRI quintile. There was no change in the five-year patient and 
graft survival probabilities between the time cohorts. Within each time cohort, patient and graft 
survival was higher at lower KDRIs. Over time there appeared to be a narrowing in the difference in 
the five-year survival probabilities between the two highest KDRI quintiles due to an improvement in 
the outcomes from the highest KDRI category.
There was no difference in the unadjusted and adjusted risk of death across transplant cohorts 
(adjusted hazard ratio, aHR: 1.19, 95%CI: 0.92-1.54 for 2007-2008, and aHR: 1.17, 95%CI: 0.74-1.83 
for 2009-2010 compared to 2005-2006, Figure 5). In addition, there was no difference in the 
unadjusted and adjusted risk of graft failure across transplant cohorts (aHR: 1.22, 95%CI: 0.98-1.50 
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of death or graft loss in patients transplanted with lower KDRI i.e., better quality, allografts, was 
lower, however, this effect was reduced when adjusting for recipient and transplant factors 
(Supplemental Figure 3). 
Sensitivity analysis
Complete case analysis yielded similar results to those obtained with the imputed dataset 
(Supplementary Tables 2, 3 and 4). Analysis of DBD kidneys only revealed slightly lower KDRI scores 
for each time point but the trend of increasing KDRI scores over time remained (Supplementary 
Tables 2 and 3). 
DISCUSSION
We investigated for trends in the quality of deceased donor kidneys expressed as a standardised 
KDRI, transplanted between 2005 and 2015, in seven European countries and the effects of these 
trends on survival outcomes. During this ten-year period, the overall quality of deceased donor 
kidneys decreased for every subgroup except for recipients aged 18-44 years. The decline in the 
overall kidney quality was evident as an increase in the standardised KDRI of approximately 1.3% per 
year, which is in line with changes seen in the US (15). The factors driving these temporal changes 
were predominantly an increased use of older deceased donors, donors with a prior diagnosis of 
hypertension or diabetes mellitus and for the Netherlands and the UK the use of DCD donors. As the 
use of donors with these risk factors varied between countries, we saw that the median standardised 
KDRI varied between countries. In countries such as the Netherlands and the UK, where in 2015, 
almost 50% of deceased donors were DCD donors; the standardised KDRI was consistently higher 
than in Norway, where only 5% of deceased donors were DCD donors. Even with the exclusion of 
DCD kidneys both the crude and standardised KDRI rose over time.  Five-year patient and graft 
survival probabilities remained unchanged despite the decrease in the overall quality of deceased 
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transplantation procedures and changes in immunosuppressive regimes. Alternatively, it is possible 
that the quality of deceased donor kidneys does not negatively affect transplantation outcomes in 
the medium term (of five years), but rather in the long term.
There are several factors which may drive the decline in the quality of deceased donor 
kidneys over time and which may vary across countries; for example, the demand for deceased 
donor organ transplantation in terms of the number of patients commencing kidney replacement 
therapy (KRT); the number of patients listed on the transplant waiting list; and the strength of the 
living donor transplant programme. It may be that the reduction in the quality of transplanted 
kidneys, by means of accepting more marginal deceased donors, is an attempt to counterbalance 
long waiting-times faced by potential transplant recipients. Secondly, the duration and success of the 
use of marginal donors within a country, is likely to affect the future number of these donors. 
Additionally, the overall organisational structure of a country’s transplantation programme, down to 
who is responsible for organ procurement may play a contributory role (16). Finally, intercountry 
differences in KDRI could be influenced by background risk factors within the general population. 
Within all these countries the prevalence of diabetes mellitus, hypertension and obesity within the 
general population varies (17) therefore the percentage of potential donors within each country with 
these features will vary. The increasing prevalence of these diseases (18-20), may well in part explain 
the trend towards increasing KDRIs. 
This study has shown that the poorest quality kidneys are being transplanted into the oldest 
recipients, this is in keeping with a single-centre German study (9). As we demonstrated; as the age 
of the recipient increased, the median standardised KDRI increased, whereas with time the youngest 
recipients received ever better-quality kidneys. It is clear that longevity matching, and therefore 
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kidneys continued, even when stratified by recipient age group, thereby disputing the idea that 
kidney quality within a country is driven predominantly by recipient qualities. 
Despite the decline in the quality of donor kidneys over the past ten years, patient and graft survival 
remained unchanged. Several factors may have contributed to improving both recipient and graft 
survival potentially counterbalancing the effects of the decline in the quality of donor kidneys. The 
risk of recipient death can be decreased, for example, by reducing cardiovascular risk factors. Ceretta 
et al., demonstrated that between 2005 and 2014 the proportion of Europeans commencing KRT 
with cardiovascular disease as a comorbidity declined (21). Furthermore Boenink et al., recently 
showed that the excess mortality risk in Europeans commencing KRT between 2002 and 2015 
decreased in relation to the improved survival in the general population (22), in other words the 
factors resulting in improved KRT outcomes are not limited to overall improvements in the health of 
the general population. It may be that overall improvements in the relative health of the potential 
kidney transplant recipient may be paying a role in counterbalancing the effects of the higher KDRI 
transplant. Though this remains speculative, and to date there is no evidence that individuals are 
being transplanted in a state of relative improved health. In addition to potential improvement in 
pre-transplantation health, there is an increased emphasis from transplant groups on the post-
transplant control of blood pressure and cardiovascular risk management (23) though again whether 
this has translated to a decline in post transplantation cardiovascular risk is unclear. Studies 
specifically assessing trends in the pre-transplantation health of European transplant recipients are 
needed to determine what is driving this apparent counterbalance in survival outcomes. 
One of the factors driving both the increase and country difference in the median 
standardised KDRI over time was the use of DCD allografts, though it should be emphasised that both 
the crude and standardised KDRI rose over time even with the exclusion of DCD kidneys. The legal 
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throughout Europe (24). Within the Netherlands and the UK, DCD donors now make up 
approximately 50% and 42% respectively of the deceased donors (25, 26). Though DCD allografts are 
typically thought to have worse outcomes than DBD allografts, recent evidence is bringing this into 
question (27). A Dutch study reported five-year death-censored graft failure for recipients aged <65 
years of DBD and DCD allografts from donors aged <65 years of 85.9% (95%CI: 84.1-87.6) and 82.6% 
(95%CI: 80.2-84.9) respectively (28). Similarly a UK study found equivalent graft outcomes between 
older controlled DCD and DBD allografts in the same age group (29), though controlled DCD allografts 
performed less well than DBD allografts with increasing donor and recipient ages, longer CIT times, 
repeat transplantation, and poor HLA matches (30). Perhaps given the survival improvement from 
DCD allografts with time, the higher KDRIs seen as a result of the DCD allografts is no longer a true 
reflection of the donor quality and hence survival is unchanged despite the higher KDRI scores.
Unlike the findings in our study, the median KDRI score in the US has remained fairly low and static 
between 2005 and 2015 at approximately 1.24 (31). Whereas in 2015, 55% of European deceased 
kidney donors died of a CVA, 64% were aged over 50 years and 37% were donors after cardiac death, 
in the US only 25% of kidney donors died of a CVA, 25% were aged over 50 years and only 18% were 
DCD donors (31) . A recent study by Aubert et al., demonstrated an almost double discard rate in the 
US as compared to France (32). A lower US discard rate similar to that of France would have resulted 
in an additional 132,445 allograft life-years. Despite the differences in the distribution of the KDRI 
score, the 5-year US and European graft survival outcomes remain similar at about 75-85% (31, 33).
The main strength of this study is its ability to compare the trends in the quality of deceased donor 
kidneys, by means of the standardised KDRI, across seven European countries, within various 
subgroups over ten years. The KDRI is an easily applicable scoring system; it allows for 






/ndt/advance-article/doi/10.1093/ndt/gfab156/6225012 by guest on 20 April 2021
15
However, in the future, in light of improved outcomes of DCD allografts, the inclusion or weighting of 
DCD donors in the KDRI score may need to be reconsidered. The main limitation of this study is the 
lack of information regarding organ discard rates and the corresponding KDRI of these organs, 
therefore we cannot form a complete picture of the potential donor kidneys available over this time 
period. Correlation with pre-implantation biopsy findings would have been useful though this 
information was not available. To have a clearer picture we have only included first transplant 
recipients and so we cannot comment on the donor quality kidney or outcomes of subsequent 
transplantations. The findings of this study are based on transplants occurring in seven European 
countries and so we may not be able to generalise these results to the rest of Europe. The relative 
sizes of the countries/regions in this study are reflected in the findings i.e., the overrepresentation of 
the UK and large swings in the country specific results from smaller countries/regions. Furthermore, 
throughout most of Europe, data on ethnicity which is included in the KDRI score is not collected. 
Given that the prevalence of ‘Black or African American’ race in the Eurotransplant zone and UK is 
low (1% in the UK (34)) we assumed all donors where Caucasian. This may have slightly 
underestimated the KDRI score. 
CONCLUSION
Over the past ten years the quality of deceased donor kidneys as expressed by standardised KDRI has 
decreased across all seven European countries examined by this study, though this did not translate 
to worse outcomes. A difference in the median kidney quality between countries and between the 
age groups was seen. As life expectancy in the general population increases, and the prevalence of 
diabetes mellitus, hypertension and obesity increases it is likely that we will continue to see poorer 
quality donor kidneys. To avoid this translating into worse transplant outcomes the transplant 
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transplant outcomes despite these lower quality allografts. This approach could further expand the 
pool of transplantable organs. 
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Box 1 Kidney donor risk index (KDRI) calculation, donor factors and model coefficients as described 
by Rao et al. (10). 
 Table 1 Additional data sources and number of recipients provided by country or region
KDRIexp = exp(−0.0194 × I[age<18 yr] × [age−18 yr] + 0.0128 × [age − 40 yr] + 0.0107 × I[age>50 yr] x [age−50 
yr] + 0.179 × I[race=African American] + 0.126 × I[hypertensive] + 0.130 × I[diabetes] + 0.220 × [SCr − 1 
mg/dl] − 0.209 × I[SCr>1.5 mg/dl] × [SCr − 1.5 mg/dl] + 0.0881× I[cause of death=CVA] − 0.0464 × [/10] − 
0.0199 × I[weight<80 kg] × [(weight − 80 kg)/5] + 0.133 × I[donation after cardiac death] + 0.240 × I[hepatitis 
C]. Where I equates to 1 if the condition is true, and I equates to 0 if the condition is false.
Donor Characteristic Applies to: KDRI Coefficient 
(“Beta”)
KDRI “XBeta” Component
Age (integer years) All donors 0.0128 0.0128*(age-40)
Donors aged <18 years -0.0194 -0.0194*(age-18)
Donors aged >50 years 0.0107 0.0107*(age-50)
Height (cm) All donors -0.0464 -0.0464*(hgt-170)/10
Weight (kg) All donors with weight <80Kg -0.0199 -0.0199*(wgt-80)/5
Ethnicity African American donors 0.1790 0.1790
History of hypertension Hypertensive donors 0.1260 0.1260
History of diabetes mellitus Diabetic donors 0.1300 0.1300
Cause of death Donors with cause of death as a 
cerebrovascular event
0.0881 0.0881
All donors 0.2200 0.2200*(creat-1.0)
Serum creatinine Donors with creatinine >1.5 mg/dL -0.2090 -0.2090*(creat-1.5)
Hepatits C status Hepatits C positive donors 0.2400 0.2400
Donation after circulatory 
status
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Table 1. Deceased kidney donor details by year of transplantation, for first kidney only transplants performed between 2005 and 2015, and the average 
annual percentage change (AAPC) and 95% confidence interval (95%CI) by donor factor, for Austria, Basque Country (Spain), Denmark, the Netherlands, 








Number 1865 1837 1852 1927 2082 2204 2255 2417 2560 2593 2585 4.2 (3.5; 4.9)*























65) 1.1 (0.7; 1.4)*
% donors with age <18 6 5 6 5 5 4 4 3 3 3 4 -6.3 (-9.1; -3.5)*
% donors with age > 50 51 51 55 53 56 59 63 63 63 64 64 2.6 (1.9; 3.3)*























(164;179) 0.0 (-0.1; 0.1)
Weight, kg, mean (SD) 75 (16.2) 76 (15.6) 76 (16.5) 76 (16.3) 77 (16.7) 78 (17.8) 77 (17.6) 78 (17.3) 78 (18.3) 78 (18.6) 78 (18.5) 0.4 (0.3; 0.5)*
% with BMI >35 kg/m2 4 4 5 4 6 5 5 6 7 8 7 6.8 (4.1;9.6)*
History of HCV, % yes 0.5 0.1 0.4 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.2 -11.8 (-20.8; -1.8)*
History of HTN, % yes 23 25 25 26 24 30 32 31 32 31 30 3.2 (1.7, 4.8)*
History of DM, % yes 4 4 5 5 6 6 7 6 7 7 8 6.5 (4.7; 8.4)*
Cause of death; CVA (%) 65 64 64 60 62 65 63 61 57 60 56 -1.2 (-1.9; -0.4)*




















1.0) -0.9 (-0.9; -0.9)*
DCD status, % yes 19 20 23 28 29 29 33 36 38 34 37 6.4 (3.4; 9.5)*
IQR: interquartile range; SD: standard deviation; BMI: body mass index; HCV: hepatitis C status, HTN: hypertension, DM: diabetes mellitus; CVA: cerebrovascular event; DCD: donation 
after circulatory death; AAPC: average annual percentage change; 95%CI: 95% confidence interval. Data is for Austria, Basque Country (Spain), Denmark, the Netherlands, Norway, 
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Table 2. Deceased donor risk factors as presented in the kidney donor risk index equation, by country/region and for the years 2005, 2010 and 2015.
Tx year Austria Basque Country (Spain) Denmark the Netherlands Norway Slovenia United Kingdom
Number of 
recipitent
2005 237 102 91 335 104 30 956
donors 2010 224 101 110 308 136 53 1259
2015 218 104 126 355 145 54 1573
Donor age, yrs 2005 51 (42; 61) 55 (43; 65) 53 (44; 60) 50 (37; 58) 55 (41; 60.7) 42 (23; 49) 49 (37; 57)
median (IQR) 2010 56 (45; 67) 62 (46; 70) 51 (44; 64) 55 (46; 62) 55 (43.6; 63) 48 (34; 54) 52 (41; 62)
2015 57 (49; 66) 62 (48; 72) 58 (44; 66) 57 (49; 66) 55 (37; 68) 53 (46; 59) 54 (43; 64)
% of donors 2005 5 2 6 8 6 23 6
<18 years 2010 3 1 4 5 4 15 4
2015 5 1 6 2 6 4 4
% of donors 2005 54 66 64 52 63 23 48
>50 years 2010 68 67 56 65 62 45 56
2015 70 70 64 73 61 61 61
Height, cm 2005 175 (168; 180) 165 (160; 175) 170 (165; 180) 174 (168; 180) 175 (165; 180) 170 (165; 175) 170 (163; 178)
median (IQR) 2010 170 (165; 180) 168 (161; 175) 175 (168; 180) 175 (167; 180) 175 (170; 180) 170 (167; 178) 170 (163; 178)
2015 172 (165; 180) 170 (160; 175) 172 (165; 180) 173 (168; 180) 171 (165; 180) 175 (165; 180) 171 (163; 178)
Weight, kg 2005 80 (16) 73 (13) 75 (17) 74 (15) 80 (21) 69 (23) 74 (16)
mean (sd) 2010 76 (16) 78 (11) 76 (16) 78 (18) 78 (19) 75 (13) 78 (19)
2015 78 (20) 74 (13) 76 (18) 78 (18) 74 (17) 79 (14) 78 (19)
Donor 2005 3 3 0 6 8 7 4
Diabetes, % 2010 8 9 4 5 4 0 6
% 2015 12 12 2 9 3 9 8
Donor 2005 33 39 27 3 25 20 20
Hypertension 2010 36 33 31 30 35 38 29
% 2015 41 35 33 29 27 30 28
Donor CVA, % 2005 60 56 75 57 54 87 68
2010 68 70 81 61 61 83 63
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Donor 2005 0.90 (0.70; 1.12) 0.80 (0.60; 1.00) 0.81 (0.63; 0.97) 0.86 (0.67; 1.05) 0.78 (0.66; 0.88) 0.74 (0.64; 0.90) 0.92 (0.74; 1.15)
creatinine, 2010 0.80 (0.64; 1.03) 0.74 (0.56; 0.90) 0.68 (0.51; 0.93) 0.77 (0.58; 0.99) 0.73 (0.55; 0.90) 0.90 (0.64; 1.10) 0.83 (0.66; 1.07)
mg/dL (IQR 2015 0.90 (0.68; 1.20) 0.70 (0.58; 0.87) 0.72 (0.59; 1.01) 0.75 (0.59; 0.88) 0.75 (0.58; 1.02) 0.89 (0.70; 1.10) 0.76 (0.59; 1.02)
DCD donor, % 2005 2 0 0 50 0 0 18
2010 2 2 0 37 0 0 40
2015 11 21 0 55 5 0 45
Tx: transplantation; IQR: interquartile range; BMI: body mass index; HCV: hepatitis C status, HTN: hypertension, DM: diabetes mellitus; CVA: cerebrovascular event; DCD: donation after 
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Table 3. Baseline characteristics of first, kidney-only transplant recipients by transplant cohort; 
cohort 
1: transplanted during 2005-2006, cohort 2: transplanted during 2007-2008, cohort 3: transplanted 
during 2009-10.
Characteristics 2005-2006 2007-2008 2009-2010 % missing
Number 3702 3779 4286
Male, % 62 63 63 0
Age at transplantation, median (IQR) 52 (42; 61) 52 (41; 61) 55 (44; 63) 0
Dialysis time, median (IQR), years 3 (2; 4) 3 (2; 5) 3 (2; 5) 0
Primary kidney disease, %
Diabetes mellitus type I & II 10 10 12
Hypertension/renovascular disease 11 12 13
Glomerulonephritis/sclerosis 21 20 19
Other 26 26 24
Missing/unknown 31 32 32 32
Initial KRT modality, %
Dialysis 79 81 81
Kidney transplant 12 15 18
Missing/unknown 9 4 0.7 4
Cold ischaemia time, hours, median (IQR) 17(14; 21) 16 (13; 20) 16 (12; 19) 13
Number of mismatches at HLA-A, B, DR 0.5
0 12 12 11
1 8 6 5
2 28 22 21
3 32 35 37
4 16 20 20
5 4 4 4.8
6 1 1 1.5
Panel Reactive Antibodies, % 58
0 78 78 77
>0-10 5 4 5
10-79 8 9 11
>79 2 3 2
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Figure legends
Figure 1. Violin plots of the crude kidney donor risk index (KDRI) for the transplant years 2005, 2010 
and 2015 for all countries combined presented; overall (left upper panel), by recipient sex (right 
upper panel), by recipient age group (left lower panel) and by recipient diabetic status (right lower 
panel). Black circle indicates median KDRI, and the yellow diamond the mean KDRI. 
Figure 2. Standardised median kidney donor risk index (KDRI) and average annual percentage change 
(AAPC and 95% confidence interval [CI]) during the years 2005 to 2015, for (a) all countries/regions 
combined and by (b) recipient sex, (c) recipient age group, and (d) recipient diabetic status. The KDRI 
is scaled relative to the median kidney donor in 2005. AAPCs with a significance level of less than 
0.05 are denoted by an asterix (*).
Figure 3. Standardised median kidney donor risk index (KDRI) and average annual percentage change 
(AAPC and 95% confidence interval [CI]) during the years 2005 to 2015, by country/region. The KDRI 
is scaled relative to the median kidney donor in 2005 for all countries combined. AAPCs with a 
significance level of less than 0.05 are denoted by an asterix (*). AT: Austria; ES: Basque Country 
(Spain); DK: Denmark; NL: Netherlands; NO: Norway; SI: Slovenia; UK: United Kingdom. 
Figure 4. Five-year unadjusted patient survival curves for patients aged ≥18 years old receiving their 
first deceased donor kidney only transplant by (a) time cohort during 2005 and 2010, and by kidney 
donor risk index (KDRI) quintiles between (b) 2005 and 2006, (c) 2007 and 2008, and (d) 2009 and 
2010, in all countries combined and five-year unadjusted graft survival curves by (e) time cohort 
during 2005 and 2010 and by kidney donor risk index (KDRI) quintiles between (f) 2005 and 2006, (g) 
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Figure 5. Five-year risk and 95% confidence interval of unadjusted and adjusted death and five-year 
risk of unadjusted and adjusted graft failure by time cohort; 2005-2006; 2007-2008; 2009-2010, for 
all countries/regions combined. Adjustments made for recipient age at transplantation, recipient sex, 
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A  Overall B  By recipient sex
C  By recipient age group* D  By recipient diabetic status
*Note different scale on y axis
All     1.00    1.00    1.04    1.02    1.05    1.08    1.12    1.14    1.12    1.12    1.12      1.30 (0.6; 2.0) Female 1.00    0.99    1.03    1.00    1.02    1.06    1.12    1.12    1.13    1.12    1.13      1.50 (1.0; 2.0)
Male     1.00    1.00    1.04    1.05    1.07    1.09   1.13    1.16    1.11    1.12    1.12      1.20 (0.8; 1.6)
18-44    0.93    0.90    0.91    0.88    0.89    0.89    0.90    0.90    0.87    0.89    0.89   –0.30 (–0.6; 2.3)
45-54    0.99    0.99    1.00    1.01    0.99    1.02    1.06    1.06    1.07    1.04    1.03   0.50 (–0.4; 1.4)
55-64    1.03    1.06    1.13    1.10    1.13    1.16    1.19    1.18    1.19    1.17    1.19   1.30 (0.5; 2.1)
>65       1.25   1.32   1.32   1.36   1.38   1.39   1.43   1.44   1.48   1.49   1.48   1.17 (1.4; 1.9)
DM          1.04    1.10    1.10    1.07   1.07    1.18    1.20   1.22    1.19    1.25    1.21      1.70 (1.0; 2.4)
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AT     0.99      1.00      1.05      1.08      1.18      1.15      1.22      1.16      1.13      1.13     1.17       1.40 (0.3; 2.5)
ES 1.11      1.08      1.13      1.10      1.15      1.24      1.50      1.32      1.11      1.28     1.27       1.80 (-0.2; 3.9)
DK     1.01      0.89      0.99      0.97      0.97      1.02      0.97      1.02      0.98      1.13     1.17       1.70 (0.5; 2.9)
NL  1.01      1.02      1.10      1.11      1.12      1.11      1.08      1.21      1.17      1.13      1.19       1.40 (0.7; 2.2)
NO    1.01      1.09      1.15      1.10      1.04      1.02      1.21      1.12      1.22      1.27      1.09       1.20 (-0.2; 2.7)
SI 0.89      0.96      1.00      1.00      0.99      0.97      0.98      0.96      0.91      1.00      1.00       0.30 (-0.6; 1.2)






















































AT  0.99 1.00 1.05 1.08     1.18 1.15 1.22 1.16 1.13 1.13 1.17 1.40 (0.3; 2.5)
ES 1.11 1.08 1.13 1.10 1.15 1.24 1.50 1.32 1.11 1.28 1.27 1.80 (–0.2; 3.9)
DK 1.01      0.89      0.99 0.97 0.97 1.02      0.97 1.02 0.98 1.13 1.17        1.70 (0.5; 2.9)
NL 1.01      1.02      1.10 1.11 1.12 1.11      1.08 1.21 1.17 1.13 1.19        1.40 (0.7; 2.2)
NO 1.01      1.09      1.15 1.10 1.04 1.02      1.21 1.12 1.22 1.27 1.09        1.20 (–0.2; 2.7)
SI 0.89      0.96      1.00 1.00 0.99 0.97      0.98 0.96 0.91 1.00 1.00        0.30 (–0.6;1.2)
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Cohort 1 (2005–2006):  85.6 (84.4; 86.8) 
Cohort 2 (2007–2008):  85.4 (84.2; 86.5) 






























0.45 to < 0.79:   90.5 (88.2; 92.4) 
0.79 to < 0.96:   90.5 (88.3; 92.3) 
0.96 to < 1.15:   87.1 (84.4; 89.3) 
1.15 to < 1.45:   82.7 (79.8; 85.2) 
> 1.45:               71.3 (66.9; 75.2)












0.45 to < 0.79:   91.6 (89.4; 93.4) 
0.79 to < 0.96:   89.9 (87.6; 91.9) 
0.96 to < 1.15:   86.3 (83.6; 88.6) 
1.15 to < 1.45:   82.1 (79.3; 84.5) 
> 1.45:               74.1 (70.2; 77.5)






























0.45 to < 0.79:   91.9 (89.6; 93.6) 
0.79 to < 0.96:   90.0 (87.7; 91.9) 
0.96 to < 1.15:   86.9 (84.4; 89.0) 
1.15 to < 1.45:   82.8 (80.2; 85.2) 
> 1.45:               75.7 (72.5; 78.5)
log rank p <0.001
Cohort 1: 2005–2006
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0.96 to < 1.15:   81.1 (78.1; 83.7) 
1.15 to < 1.45:   72.6 (69.3; 75.6) 
> 1.45:               66.0 (61.4; 70.1)
log rank p <0.001
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log rank p <0.001
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log rank p <0.001
0.45 to < 0.79:   89.2 (86.7; 91.2)
0.79 to < 0.96:   84.4 (81.7; 86.7) 
0.96 to < 1.15:   81.9 (79.2; 84.4) 
1.15 to < 1.45:   77.0 (74.1; 79.7) 
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2 3
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1.03 (0.91; 1.16) 
1.02 (0.91; 1.15) 
1
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1
Hazard ratio
A  Unadjusted overall survival
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